Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of the PARG inhibitor ETX-19477 in advanced solid malignancies
2024-518326-32-00Phase 2Authorised
- Sponsor
- 858 Therapeutics
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of ETX-19477 in Nonhematologic neoplasms (2 arms), sponsored by 858 Therapeutics. Planned start Jul 2026; status: authorised.
02
Drugs
ETX-19477
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-518326-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518326-32-00.